1. Inicio
  2. Proyectos y Estudios Clínicos
  3. A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF)

A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF)

Datos básicos

Código:
1462-0004
Protocolo:
1462-0004
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
Dotación:
Año de incio:
2024
Año de finalización:
ENSAYOS CLÍNICOS

Objetivos del proyecto

The primary objectives are to demonstrate a non-flat dose response curve based on the annual rate of decline in FVC up to 52 weeks of treatments, using three different oral doses of BI 1819479 (0.3 mg qw, 0.1 mg qd, 0.6 mg qd), and to evaluate the quantitative treatment effect size and the dose-response relationship.

Unidades de investigación

Documentos

  • No hay documentos

Participantes

Financiadores - Promotores

Boehringer Ingelheim España, S.A.

Compartir